Europäische Union - Deutsch - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunsuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium - ibuprofen - pulver zum einnehmen im beutel - 200 mg - ibuprofen 200 mg - ibuprofen

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium - ibuprofen - pulver zum einnehmen im beutel - 400 mg - ibuprofen 400 mg - ibuprofen

Europäische Union - Deutsch - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskuläre blockade - alle anderen therapeutischen produkte - umkehrung der neuromuskulären blockade durch rocuronium oder vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

seacross pharma (europe) limited (8184991) - injektionslösung - 20 mg/ml

Europäische Union - Deutsch - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - migräne-störungen - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Europäische Union - Deutsch - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastische mittel - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.